AI
TVRD

AdvisorShares Investments’s Tvardi Therapeutics TVRD Stock Holding History

AdvisorShares Investments’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,364
Closed -$1.12M – 129
2020
Q1 		$1.12M Buy
2,364
+147
+7% +$79.9K 0.98% 15
2019
Q4 		$1.29M Buy
+2,217
New +$1.56M 0.8% 19

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AdvisorShares Investments's TVRD Position: Q2 2020 in Review

AdvisorShares Investments sold out of Tvardi Therapeutics (TVRD) in Q2 2020, closing a stake of 2,364 shares — an estimated $1.12M sold.

AdvisorShares Investments first reported a position in TVRD in Q4 2019 and held it in 2 quarters. The position peaked at $1.29M in Q4 2019. 146 funds tracked by Wall St. Rank hold TVRD as of Q2 2020.

  • AdvisorShares Investments reported no remaining Tvardi Therapeutics position as of Q2 2020 after selling out during the quarter.
  • AdvisorShares Investments sold 2,364 Tvardi Therapeutics shares in Q2 2020, an estimated $1.12M.
  • AdvisorShares Investments first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 2 quarters.
  • AdvisorShares Investments's Tvardi Therapeutics position peaked at $1.29M in Q4 2019.
  • 146 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2020.

Based on AdvisorShares Investments's 13F filing for Q2 2020, filed 14 Jul 2020.